Beta Competitors

BETA Stock   2,143  103.15  4.59%   
Beta Drugs competes with Reliance Industries, Tata Consultancy, HDFC Bank, and Bharti Airtel; as well as few others. Analyzing Beta Drugs competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Beta Drugs to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Beta Drugs Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Beta Drugs competition on your existing holdings.
  
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
1,9292,1732,176
Details
Intrinsic
Valuation
LowRealHigh
1,9292,4652,469
Details
Naive
Forecast
LowNextHigh
2,2002,2042,207
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1,7332,0162,299
Details

Beta Drugs Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Beta Drugs and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Beta and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Beta Drugs does not affect the price movement of the other competitor.
Click cells to compare fundamentals   Check Volatility   Backtest Portfolio
High positive correlations   
TCSRELIANCE
BHARTIARTLRELIANCE
BHARTIARTLHDFCBANK
  
High negative correlations   
HDFCBANKTCS
HDFCBANKRELIANCE
BHARTIARTLTCS

Risk-Adjusted Indicators

There is a big difference between Beta Stock performing well and Beta Drugs Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Beta Drugs' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

Beta Drugs Competitive Analysis

The better you understand Beta Drugs competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Beta Drugs' competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Beta Drugs' competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
BETA RELIANCE TCS HDFCBANK BHARTIARTL
 4.59 
 2,143 
Beta
 1.73 
 1,271 
Reliance
 2.02 
 4,245 
Tata
 1.06 
 1,793 
HDFC
 1.09 
 1,560 
Bharti
Market Volatility
(90 Days Market Risk)
Market Performance
(90 Days Performance)
Odds of Financial Distress
(Probability Of Bankruptcy)
Current Valuation
(Equity Enterprise Value)
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Net Asset
Profit Margin
EBITDA
Operating Margin
Current Valuation
Price To Book
Retained Earnings
Beta
Number Of Employees
Shares Outstanding
Cash Flow From Operations
Annual Yield
Total Debt
Return On Equity
Return On Asset
Book Value Per Share
Total Asset
Target Price
Last Dividend Paid
Shares Owned By Institutions
Market Capitalization
Price To Earnings To Growth
Price To Sales
Net Income
Earnings Per Share
Shares Owned By Insiders
Revenue
Working Capital
Cash And Equivalents
Gross Profit
Day Typical Price
Accumulation Distribution
Market Facilitation Index
Daily Balance Of Power
Period Momentum Indicator
Rate Of Daily Change
Day Median Price
Price Action Indicator
Coefficient Of Variation
Mean Deviation
Jensen Alpha
Total Risk Alpha
Sortino Ratio
Downside Variance
Standard Deviation
Kurtosis
Potential Upside
Treynor Ratio
Maximum Drawdown
Variance
Market Risk Adjusted Performance
Risk Adjusted Performance
Skewness
Semi Deviation
Information Ratio
Value At Risk
Expected Short fall
Downside Deviation
Semi Variance

Beta Drugs Competition Performance Charts

Five steps to successful analysis of Beta Drugs Competition

Beta Drugs' competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Beta Drugs in relation to its competition. Beta Drugs' competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Beta Drugs in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Beta Drugs' competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Beta Drugs, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Beta Drugs position

In addition to having Beta Drugs in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Preferred Stock ETFs Thematic Idea Now

Preferred Stock ETFs
Preferred Stock ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Preferred Stock ETFs theme has 16 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Preferred Stock ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Beta Stock Analysis

When running Beta Drugs' price analysis, check to measure Beta Drugs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Beta Drugs is operating at the current time. Most of Beta Drugs' value examination focuses on studying past and present price action to predict the probability of Beta Drugs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Beta Drugs' price. Additionally, you may evaluate how the addition of Beta Drugs to your portfolios can decrease your overall portfolio volatility.